Reinforcing effects of cathinone NPS in the intravenous drug self-administration paradigm

Current Topics in Behavioral Neurosciences

Volumn 32, Issue , 2016, Pages 133-143

  Watterson, Lucas R ^a   Olive, M Foster ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Animal model; Cathinone; Intravenous self administration; Operant conditioning; Reinforcement

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; CATHA EDULIS EXTRACT; CATHINONE; COCAINE; DOPAMINE; METHAMPHETAMINE; METHYLONE; MIDOMAFETAMINE; NORADRENALIN; PYROVALERONE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; ALKALOID; CENTRAL STIMULANT AGENT; PSYCHOTROPIC AGENT; PYRROLIDINE DERIVATIVE;

AGGRESSION; ALERTNESS; CONTROLLED STUDY; DELIRIUM; DELUSION; ENERGY; EUPHORIA; HALLUCINATION; INTRAVENOUS DRUG ABUSE; LIBIDO; NONHUMAN; PARANOIA; PRIORITY JOURNAL; RAT; REINFORCEMENT; VEIN CATHETERIZATION; VIOLENCE; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; DRUG SELF ADMINISTRATION; INSTRUMENTAL CONDITIONING; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ALKALOIDS; ANIMALS; BEHAVIOR, ANIMAL; BENZODIOXOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONDITIONING, OPERANT; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOTROPIC DRUGS; PYRROLIDINES; RATS; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION;

EID: 85017519216     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2016_33     Document Type: Chapter

References (55)

1. Association of Poison Control Centers (2013) Bath salts data. 30 April 2013
2. Baumeister D, Tojo LM, Tracy DK (2015) Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol 5:97-132
3. Karch SB (2015) Cathinone neurotoxicity (“the 3Ms”). Curr Neuropharmacol 13:21-25
4. Underwood E (2015) A new drug war. Science 347:469-473
5. Weaver MF, Hopper JA, Gunderson EW (2015) Designer drugs 2015: assessment and management. Addict Sci Clin Pract 10:8
6. Zawilska JB (2015) “Legal highs” - an emerging epidemic of novel psychoactive substances. Int Rev Neurobiol 120:273-300
7. Banks ML, Worst TJ, Rusyniak DE, Sprague JE (2014) Synthetic cathinones (“bath salts”). J Emerg Med 46:632-642
8. Froberg BA, Levine M, Beuhler MC, Judge BS, Moore PW, Engebretsen KM, McKeown NJ, Rosenbaum CD, Young AC, Rusyniak DE (2015) Acute methylenedioxypyrovalerone toxicity. J Med Toxicol 11:185-194
9. Hall C, Heyd C, Butler C, Yarema M (2014) “Bath salts” intoxication: a new recreational drug that presents with a familiar toxidrome. CJEM 16:171-176
10. Karila L, Megarbane B, Cottencin O, Lejoyeux M (2015) Synthetic cathinones: A new public health problem. Curr Neuropharmacol 13:12-20
11. Batisse A, Fortias M, Bourgogne E, Gregoire M, Sec I, Djezzar S (2014) Case series of 21 synthetic cathinones abuse. J Clin Psychopharmacol 34:411-413
12. Baumann MH (2014) Awash in a sea of ‘bath salts’: implications for biomedical research and public health. Addiction 109:1577-1579
13. Capriola M (2013) Synthetic cathinone abuse. Clin Pharmacol Adv Appl 5:109-115
14. Fass JA, Fass AD, Garcia AS (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 46:436-441
15. Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D (2014) Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil 5:37-52
16. Sadeg N, Darie A, Vilamot B, Passamar M, Frances B, Belhadj-Tahar H (2014) Case report of cathinone-like designer drug intoxication psychosis and addiction with serum identification. Addict Disord Treat 13:38-43
17. Winder GS, Stern N, Hosanagar A (2013) Are “bath salts” the next generation of stimulant abuse? J Subst Abuse Treat 44:42-45
18. Watterson LR, Olive MF (2014) Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv Neurosci 2014:209875
19. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552-562
20. Cameron K, Kolanos R, Verkariya R, De Felice L, Glennon RA (2013) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl) 227:493-499
21. Cameron KN, Kolanos R, Solis E, Glennon RA, De Felice LJ (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750-1757
22. Coppola M, Mondola R (2012) 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208: 12-15
23. De Felice LJ, Glennon RA, Negus SS (2014) Synthetic cathinones: Chemical phylogeny, physiology, and neuropharmacology. Life Sci 97:20-26
24. Glennon RA (2014) Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv Pharmacol 69:581-620
25. Kolanos R, Partilla JS, Baumann MH, Hutsell BA, Banks ML, Negus SS, Glennon RA (2015) Stereoselective actions of methylenedioxypyrovalerone (MDPV) to inhibit dopamine and norepinephrine transporters and facilitate intracranial self-stimulation in rats. ACS Chem Neurosci 6:771-777
26. Kolanos R, Solis EJ, Sakloth F, De Felice LJ, Glennon RA (2013) “Deconstruction” of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem Neurosci 4:1524-1529
27. Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener M, Liechti M (2013) Pharmacological characterization of designer cathinones in vitro. J Comp Neurol 168:458-470
28. Baumann MH, Ayestas MA Jr., Partilla JS, Sink JR., Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192-1203
29. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803-1815
30. Lopez-Arnau R, Martinez-Clemente J, Carbo M, Pubill D, Escubedo E, Camarasa J (2013) An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts”. Prog Neuropsychopharmacol Biol Psychiatry 45: 64-72
31. Cozzi NV, Sievert MK, Shulgin AT, Jacob P III, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by Beta-keto amphetamines. Eur J Pharmacol 381:63-69
32. Pifl C, Reither H, Hornykiewicz O (2015) The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter. Eur J Pharmacol 755:119-126
33. Gosnell BA, Yracheta JM, Bell SM, Lane KE (1996) Intravenous self-administration of cathinone by rats. Behav Pharmacol 7:526-531
34. Kaminski BJ, Griffiths RR (1994) Intravenous self-injection of methcathinone in the baboon. Pharmacol Biochem Behav 47:981-983
35. Woolverton WL, Johanson CE (1984) Preference in rhesus monkeys given a choice between cocaine and d, l-cathinone. J Exp Anal Behav 41:35-43
36. Watterson LR, Watterson E, Olive MF (2013) Abuse liability of novel ‘legal high’ designer stimulants: evidence from animal models. Behav Pharmacol 24:341-355
37. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530-536
38. Aarde SM, Angrish D, Barlow DJ, Wright MJJ, Vandewater SA, Creehan KM, Houseknecht KL, Dickerson TJ, Taffe MA (2013) Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol 18:768-799
39. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L (2006) Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 186:48-53
40. Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM, Wyatt N, Callaghan PD, Bowen MT, Cornish JL, McGregor IS (2013) High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine. J Psychopharmacol 27:823-836
41. Creehan KM, Vandewater SA, Taffe MA (2015) Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92:90-97
42. Vandewater SA, Creehan KM, Taffe MA (2015) Intravenous self-administration of entactogen-class stimulants in male rats. Neuropharmacology 99:538-545
43. Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats. Neuropharmacology 71:130-140
44. Aarde SM, Huang PK, Dickerson TJ, Taffe MA (2015) Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats. Psychopharmacology (Berl) 232:1867-1877
45. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19:165-174
46. Schindler CW, Thorndike EB, Goldberg SR, Lehner KR, Cozzi NV, Brandt SD, Baumann MH (2016) Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylene-dioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology (Berl) 233:1981-1990
47. Watterson LR, Hood LE, Sewalia K, Johnson CT, Wegner S, Grabenauer M, Thomas BF, Marusich JA, Olive MF (2012) The reinforcing effects of the methylone, a synthetic cathinone commonly found in “bath salts”. J Addict Res Ther S9:002
48. Watterson LR, Burrows BT, Hernandez RD, Moore KN, Grabenauer M, Marusich JA, Olive MF (2014) Effects of α-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation “bath salts,” on intracranial self-stimulation thresholds in rats. Int J Neuropsychopharmacol 18:1-9
49. Aarde SM, Creehan KM, Vandewater SA, Dickerson TJ, Taffe MA (2015) In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology (Berl) 232: 3045-3055
50. Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206-213
51. Roberts DCS, Phelan R, Hodges LM, Hodges MM, Bennett B, Childers S, Davies H (1999) Self-administration of cocaine analogs by rats. Psychopharmacology (Berl) 144:389-397
52. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848-854
53. Wee S, Carroll FI, Woolverton WL (2006) A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology 31:351-362
54. Gass JT, Olive MF (2008) Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 75:218-265
55. Liberles SD (2015) Trace amine-associated receptors: ligands, neural circuits, and behaviors. Curr Opin Neurobiol 34:1-7